OBJECTIVE： To evaluate the effects of clinical pharmacists participating in disease management of chronic heart failure （CHF）. METHODS： A total of 180 CHF inpatients selected from cardiovascular medicine department of our hospital during Jan. 2013 to Dec. 2014 were divided into control group and pharmacist management group according to random number table， with 90 cases in each group. The control group was given routine treatment. The pharmacist management group additionally received individualized pharmaceutical care， such as pharmaceutical monitoring， psychological counseling， medication education and 6-month follow-up. The comprehensive self-care ability of the 2 groups were compared on admission and on discharge； re-hospitalization and mortality were compared between 2 groups within 6 months after discharged； the patients’ NYHA classification， LVEF， plasma level of NT-proBNP and quality of life were compared between 2 groups on admission and 6 months after discharge. RESULTS： There was no statistical significance in the cognition of patients to disease， self-care ability， medication compliance score and total comprehensive self-care ability score between 2 groups on admission （P＞0.05）. Each score and total score of 2 groups were better on discharge than on admission， and the pharmacist management group was better than control group， with statistical significance （P＜0.05）. Within 6 months after discharge， re-hospitalization rate of pharmacist management group was significantly lower than that of control group， with statistical significance （P＜0.05）. There was no statistical significance in mortality rate between 2 groups （P＞0.05）. There was no statistical significance in NYHA classification， LVEF， plasma level of NT-proBNP between 2 groups on admission （P＞0.05）. 6 months after discharge， the above 3 indexes of pharmacist management group as well as NYHA classification and plasma level of NT-proBNP of control group were improved significantly compared to on admission； NYHA classification， LVEF and plasma level of NT-proBNP of pharmacist management group were better than those of control group at corresponding period， with statistical significance （P＜0.05）. There was no statistical significance in social limit， mood， symptom score and total score of life quality between 2 groups on admission （P＞0.05）. 6 months after discharge， each score and total score of 2 groups were all better than on admission， and the pharmacist management group was better than control group， with statistical significance （P＜0.05）. CONCLUSIONS： The participation of clinical pharmacists in the disease management of CHF can significantly improve comprehensive self-care ability， decrease re-hospitalization rate， ameliorate cardiac function and enhance the quality of life.